Anthropic Says It Will Revolutionize Biology—Some Day
wired ·
Anthropic has significantly tempered its ambitious claims regarding the immediate revolution of biology and drug discovery in its recent IPO filing, contrasting sharply with previous statements by CEO Dario Amodei. While Amodei previously suggested AI could compress decades of scientific progress into mere years or cure most diseases within a decade, the regulatory documents acknowledge the company's lack of experience in physical experimentation. The filing highlights that biological research requires handling hazardous materials, operating laboratory equipment, and navigating complex regulations, which are outside Anthropic's traditional software expertise. Furthermore, the company adopted more cautious language regarding a 'Crispr-like' enzyme discovered by Claude, noting it might only have potential rather than guaranteeing utility. This shift indicates that Anthropic now views biotech as a core business component subject to the same lengthy, costly, and uncertain development timelines as established pharmaceutical firms. Despite these sobering realities, the company maintains that AI will profoundly accelerate progress, even if the journey from digital prediction to clinical application remains slow. Ultimately, the filing underscores that despite computational power, proving safety and efficacy through human trials cannot be hastened simply by adding more computing resources.
wired